Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Dennis J. Meisner

Hematology Oncology | Hematology | Oncology
3204 Johnson Rd, Suite 10, 
Steubenville, OH 
Advanced in Embryonal Tumor with Multilayered Rosettes
3204 Johnson Rd, Suite 10, 
Steubenville, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dennis Meisner is a Hematologist Oncology specialist and a Hematologist in Steubenville, Ohio. Dr. Meisner is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Colorectal Cancer, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma.

His clinical research consists of participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

3204 Johnson Rd, Suite 10, Steubenville, OH 43952

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sonikpreet Aulakh
Hematology Oncology | Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sonikpreet Aulakh
Hematology Oncology | Hematology | Oncology

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (61.8 miles away)
304-598-4865
Languages Spoken:
English
See accepted insurances

Sonikpreet Aulakh is a Hematologist Oncology specialist and a Hematologist in Morgantown, West Virginia. Dr. Aulakh is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neuroepithelioma, Atypical Teratoid Rhabdoid Tumor (ATRT), Gliosarcoma, and Glioblastoma.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sunitha Vemulapalli
Hematology Oncology | Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sunitha Vemulapalli
Hematology Oncology | Hematology | Oncology

Aultman Cancer Care LLC

2600 6th St Sw, 
Canton, OH 
 (49.0 miles away)
330-438-6333
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sunitha Vemulapalli is a Hematologist Oncology specialist and a Hematologist in Canton, Ohio. Dr. Vemulapalli is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Lung Cancer, Breast Cancer, Thrombocytopenia, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Vemulapalli is currently accepting new patients.

Shirley S. Ong
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Shirley S. Ong
Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Shirley S. Ong
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
 (38.7 miles away)
412-756-3168
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shirley Ong, MD, specializes in hematology oncology and is board-certified in neurology by the American Board of Psychiatry and Neurology. She practices at UPMC Hillman Cancer Center and is affiliated with UPMC Shadyside and UPMC Presbyterian. Dr. Ong received her medical degree from the University of the East Ramon Magsaysay Memorial Medical Center and completed her residency at Saint Louis University School of Medicine, followed by a fellowship at the University of Texas MD Anderson Cancer Center. Dr. Ong is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meisner's expertise for a condition
ConditionClose
    View All 33 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile